PSS5 THE COST-EFFECTIVENESS OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A CANADIAN ANALYSIS
Lakzadeh, P., Lozano-Ortega, G., Gaudet, V., Johnston, K., Barbeau, M.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.1777
Date:
May, 2019
File:
PDF, 654 KB
english, 2019